Robert L. Ferrara - 11 Sep 2025 Form 4/A - Amendment Insider Report for Phio Pharmaceuticals Corp. (PHIO)

Role
Director
Signature
/s/ Lisa C. Carson, Attorney-in-fact
Issuer symbol
PHIO
Transactions as of
11 Sep 2025
Net transactions value
$0
Form type
4/A - Amendment
Filing time
15 Sep 2025, 16:02:03 UTC
Date Of Original Report
15 Sep 2025
Previous filing
11 Jun 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Ferrara Robert L Director C/O PHIO PHARMACEUTICALS CORP., 411 SWEDELAND RD., STE 23-1080, KING OF PRUSSIA /s/ Lisa C. Carson, Attorney-in-fact 15 Sep 2025 0001792987

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PHIO Common Stock, $.0001 par value Award $0 +23,100 +147% $0.000000 38,766 11 Sep 2025 Direct F1, F2, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares underlying a restricted stock unit, which shares will vest on the first annual anniversary of the grant.
F2 Includes shares of common stock underlying unvested restricted stock units.
F3 The number of reported securities has been adjusted to reflect prior reverse stock splits.
F4 This amended Form 4 corrects the number of stock options reported in the original Form 4 filed on September 15, 2025. The original filing incorrectly stated that 23,000 restricted stock units were granted. The correct number of restricted stock units granted was 23,100. Securities beneficially owned changed from 38,666 to 38,766.